---
title: "Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Pharmacokinetics"
description: "Formulary evidence on Darovasertib (IDE196, LXS196) in First-line metastatic uveal melanoma, in combination with crizotinib: Pharmacokinetics. Topics: Absorption and terminal half-life of single-agent darovasertib under fasting conditions; Accumulation, variability, and dose proportionality of single-agent darovasertib; Pharmacokinetic sampling and parameters in the first-in-human study; Absorption and tolerability in preclinical species; 3 further topics. 7 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description/pharmacokinetics"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Pharmacokinetics

<a id="heading-2.1.2.6.3"></a>

## 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

### Absorption and terminal half-life of single-agent darovasertib under fasting conditions

> “During the dose escalation part of the study, following oral doses of 100–1000 mg QD and 200–400 mg BID, total plasma concentration profiles of LXS196 showed rapid absorption in fasting conditions with a Tmax of ~1 h after dose (median Tmax ranging from 0.483–2.00 h) and consistent terminal T1/2 across different doses (~11 h).”
> “The mean terminal half-life (T1/2) was consistent across tested dose groups ranging from 8.49–13.8 h.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-2.1.2.6.3-2"></a>

### Accumulation, variability, and dose proportionality of single-agent darovasertib

> “Minimal or reduced accumulation was observed with repeated administration (mean Racc ranged from 0.718 to 1.27-fold).”
> “PK variability was moderate, as illustrated by the between-patient variability (CV%) for Cmax and for AUC0–t.”
> “Increase in exposure (AUC0–t and Cmax) on C1D1 and D15 was under-proportional to the increase in dose with both QD and BID schedules.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-2.1.2.6.3-3"></a>

### Pharmacokinetic sampling and parameters in the first-in-human study

> “In the dose escalation part of the study, PK samples were collected at various pre- and post-dose time points on C1D1, D2, D3, D15 and D16.”
> “PK parameters included area under the curve (AUC0–12h), maximum concentration (Cmax) and time to Cmax (Tmax) on C1D1 and C1D15, and additionally, the accumulation ratio (Racc) of AUC0–t on C1D15 compared to that on C1D1.”

Source: [Piperno-Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10006169/)

<a id="topic-2.1.2.6.3-4"></a>

### Absorption and tolerability in preclinical species

> “The lead series was optimized for kinase and off target selectivity to afford a compound that is rapidly absorbed and well tolerated in preclinical species.”

Source: [Visser et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38198520/)

<a id="topic-2.1.2.6.3-5"></a>

### Pharmacokinetic endpoints in the OptimUM-02 EU trial record

> “Dose-exposure-response (S&E) relationship; Plasma concentration profiles and PK parameters”

Source: [EU CTIS 2023-506686-66-01](https://euclinicaltrials.eu/ctis-public-api/retrieve/2023-506686-66-01)

<a id="topic-2.1.2.6.3-6"></a>

### Darovasertib pharmacokinetics in combination with crizotinib

No evidence found.

<a id="topic-2.1.2.6.3-7"></a>

### Crizotinib label: steady state, absorption, and effect of food

> “Following XALKORI 250 mg capsules twice daily, steady-state was reached within 15 days with a median accumulation ratio of 4.8.”
> “Steady-state minimum concentration (Cmin.ss) and AUC increased in a greater than dose-proportional manner over the dose range of 200 mg to 300 mg twice daily (0.8 to 1.2 times the approved recommended dosage).”
> “A single crizotinib capsule dose was absorbed with median time to achieve peak concentration (Tmax) of 4 to 6 hours, and the mean absolute bioavailability of 43% (range: 32% to 66%).”
> “A high-fat meal, reduced AUC0-INF and maximum plasma concentration (Cmax) of crizotinib each by 14% for the capsule formulation; reduced AUC0-INF and Cmax of crizotinib by 15% and 23%, respectively, for the pellet formulation as compared to those under fasted conditions.”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

<a id="topic-2.1.2.6.3-8"></a>

### Crizotinib label: distribution, elimination, metabolism, and excretion

> “The geometric mean volume of distribution (Vss) of crizotinib was 1772 L following a single intravenous dose.”
> “Protein binding of crizotinib is 91% and is independent of drug concentration in vitro.”
> “The mean apparent plasma terminal half-life of crizotinib was 42 hours following single doses of crizotinib in patients.”
> “The mean apparent clearance (CL/F) of crizotinib was lower at steady-state (60 L/h) after 250 mg twice daily than after a single 250 mg oral dose (100 L/h).”
> “Crizotinib is predominantly metabolized by CYP3A.”
> “Following administration of a single oral 250 mg dose of radiolabeled crizotinib dose to healthy subjects, 63% (53% as unchanged) of the administered dose was recovered in feces and 22% (2.3% as unchanged) in urine.”
> “No clinically significant difference in crizotinib pharmacokinetics were observed based on age, sex, or ethnicity (Asian, non-Asian).”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

## Related pages
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Terms and abbreviations](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations.md)
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Product information and disease description](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Clinical evidence](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic information and modeling report](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: References](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references.md)
